Praxis FDA Filings Shift Focus From Pipeline Promise To Potential Revenue [Yahoo! Finance]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Yahoo! Finance
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Praxis Precision Medicines (NasdaqGS:PRAX) has submitted two new drug applications to the FDA for ulixacaltamide and relutrigine. The filings mark a key step in the company's push to move from a clinical focus toward potential commercialization in neuroscience. For investors watching NasdaqGS:PRAX, the twin FDA submissions come at a time when the stock is trading at $293.95 and has shown very large gains over the past 1 year and roughly 19x over 3 years. The shares have seen a 5.4% decline over the past week and a 9.1% decline over the past month, while still being up 2.6% year to date and showing a 42.3% decline over 5 years, underscoring how event driven this name can be. With ulixacaltamide and relutrigine now under FDA review, Praxis Precision Medicines is entering a new phase that could reshape how the market thinks about the company. Investors may focus more close
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines (PRAX) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit [Yahoo! Finance]Yahoo! Finance
- Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization? [Yahoo! Finance]Yahoo! Finance
- This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter [Yahoo! Finance]Yahoo! Finance
- Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run? [Yahoo! Finance]Yahoo! Finance
PRAX
Earnings
- 2/19/26 - Miss
PRAX
Sec Filings
- 2/19/26 - Form S-8
- 2/19/26 - Form 10-K
- 2/19/26 - Form 8-K
- PRAX's page on the SEC website